The Indonesian Journal of Infectious Diseases最新文献_第3页

Polio by the Numbers-A Global Perspective. 小儿麻痹症的数字-全球视角。

The Indonesian Journal of Infectious Diseases Pub Date : 2022-10-17 DOI: 10.1093/infdis/jiac130

Kamran Badizadegan, Dominika A Kalkowska, Kimberly M Thompson

{"title":"Polio by the Numbers-A Global Perspective.","authors":"Kamran Badizadegan, Dominika A Kalkowska, Kimberly M Thompson","doi":"10.1093/infdis/jiac130","DOIUrl":"10.1093/infdis/jiac130","url":null,"abstract":"Background: Investments in national immunization programs and the Global Polio Eradication Initiative (GPEI) have resulted in substantial reductions in paralytic polio worldwide. However, cases prevented because of investments in immunization programs and GPEI remain incompletely characterized.Methods: Using a global model that integrates polio transmission, immunity, and vaccine dynamics, we provide estimates of polio incidence and numbers of paralytic cases prevented. We compare the results with reported cases and estimates historically published by the World Health Organization.Results: We estimate that the existence and use of polio vaccines prevented 5 million cases of paralytic polio for 1960-1987 and 24 million cases worldwide for 1988-2021 compared to a counterfactual world with no polio vaccines. Since the 1988 resolution to eradicate polio, our estimates suggest GPEI prevented 2.5-6 million cases of paralytic polio compared to counterfactual worlds without GPEI that assume different levels of intensity of polio vaccine use in routine immunization programs.Conclusions: Analysis of historical cases provides important context for understanding and communicating the benefits of investments made in polio eradication. Prospective studies will need to explore the expected benefits of future investments, the outcomes of which will depend on whether and when polio is globally eradicated.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"44 1","pages":"1309-1318"},"PeriodicalIF":0.0,"publicationDate":"2022-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556648/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81286799","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Population-level relative effectiveness of the COVID-19 vaccines and the contribution of naturally acquired immunity COVID-19疫苗的人群水平相对有效性和自然获得性免疫的贡献

The Indonesian Journal of Infectious Diseases Pub Date : 2022-10-04 DOI: 10.1101/2022.10.04.22280689

Kayoko Shioda, Yang-ling Chen, M. Collins, B. Lopman

{"title":"Population-level relative effectiveness of the COVID-19 vaccines and the contribution of naturally acquired immunity","authors":"Kayoko Shioda, Yang-ling Chen, M. Collins, B. Lopman","doi":"10.1101/2022.10.04.22280689","DOIUrl":"https://doi.org/10.1101/2022.10.04.22280689","url":null,"abstract":"Background: Immune protection against SARS-CoV-2 can be induced by natural infection or vaccination or both. The interaction between vaccine-induced immunity and naturally acquired immunity at the population level has been understudied. Methods: We used regression models to evaluate whether the impact of COVID-19 vaccines differed across states with different levels of naturally acquired immunity from March 2021 to April 2022 in the United States. Analysis was conducted for three evaluation periods separately (Alpha, Delta, and Omicron waves). As a proxy of the proportion of the population with naturally acquired immunity, we used either the reported seroprevalence or the estimated proportion of the population ever infected in each state. Results: COVID-19 mortality decreased as the coverage of [≥]1 dose increased among people [≥]65 years of age, and this effect did not vary by seroprevalence or the proportion of the total population ever infected. Seroprevalence and the proportion ever infected were not associated with COVID-19 mortality, after controlling for vaccine coverage. These findings were consistent in all evaluation periods. Conclusions: COVID-19 vaccination was associated with a sustained reduction in mortality at the state level during the Alpha, Delta, and Omicron periods. The effect did not vary by naturally acquired immunity.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"37 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"85878022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Effectiveness and Duration of Protection of a Fourth Dose of COVID-19 mRNA Vaccine among Long-Term Care Residents in Ontario, Canada 加拿大安大略省长期护理居民第四剂COVID-19 mRNA疫苗的有效性和保护时间

The Indonesian Journal of Infectious Diseases Pub Date : 2022-09-30 DOI: 10.1101/2022.09.29.22280526

R. Grewal, Leann Nguyen, S. Buchan, S. Wilson, Andrew P Costa, Jeffrey C Kwong

{"title":"Effectiveness and Duration of Protection of a Fourth Dose of COVID-19 mRNA Vaccine among Long-Term Care Residents in Ontario, Canada","authors":"R. Grewal, Leann Nguyen, S. Buchan, S. Wilson, Andrew P Costa, Jeffrey C Kwong","doi":"10.1101/2022.09.29.22280526","DOIUrl":"https://doi.org/10.1101/2022.09.29.22280526","url":null,"abstract":"Background: As of December 30, 2021, Ontario long-term care (LTC) residents who received a third dose of COVID-19 vaccine [≥]84 days previously were offered a fourth dose to prevent a surge in COVID-19-related morbidity and mortality due to the Omicron variant. Seven months have passed since fourth doses were implemented, allowing for the examination of fourth dose protection over time. Methods: We used a test-negative design and linked databases to estimate the marginal effectiveness (4 versus 3 doses) and vaccine effectiveness (VE; 2, 3, or 4 doses versus no doses) of mRNA vaccines among Ontario LTC residents aged [≥]60 years who were tested for SARS-CoV-2 between December 30, 2021 and August 3, 2022. Outcome measures included any Omicron infection, symptomatic infection, and severe outcomes (hospitalization or death). Results: We included 21,275 Omicron cases and 273,466 test-negative controls. The marginal effectiveness of a fourth dose <84 days ago compared to a third dose received [≥]84 days ago was 23% (95% Confidence Interval [CI] 17-29%), 36% (95%CI 26-44%), and 37% (95%CI 24-48%) against SARS-CoV-2 infection, symptomatic infection, and severe outcomes, respectively. Additional protection provided by a fourth dose compared to a third dose was negligible against all outcomes [≥]168 days after vaccination. Compared to unvaccinated individuals, vaccine effectiveness (VE) of a fourth dose decreased from 49% (95%CI 44%-54%) to 18% (95%CI 5-28%) against infection, 69% (95%CI 62-75%) to 44% (95%CI 24-59%) against symptomatic infection, and 82% (95%CI 77-86%) to 74% (95%CI 62-82%) against severe outcomes <84 days versus [≥]168 days after vaccination. Conclusions: Our findings suggest that fourth doses of mRNA COVID-19 vaccines provide additional protection against Omicron-related outcomes in LTC residents, but the protection wanes over time, with more waning seen against infection than severe outcomes.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"41 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-09-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"90573292","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 3

In Elimination Settings, Measles Antibodies Wane After Vaccination but Not After Infection: A Systematic Review and Meta-Analysis. 在消除环境中，麻疹抗体在接种疫苗后减弱，但在感染后不会减弱：一项系统综述和荟萃分析。

The Indonesian Journal of Infectious Diseases Pub Date : 2022-09-28 DOI: 10.1093/infdis/jiac039

Shelly Bolotin, Selma Osman, Stephanie L Hughes, Archchun Ariyarajah, Andrea C Tricco, Sumaiya Khan, Lennon Li, Caitlin Johnson, Lindsay Friedman, Nazish Gul, Rachel Jardine, Maryrose Faulkner, Susan J M Hahné, Jane M Heffernan, Alya Dabbagh, Paul A Rota, Alberto Severini, Mark Jit, David N Durrheim, Walter A Orenstein, William J Moss, Sebastian Funk, Nikki Turner, William Schluter, Jaleela S Jawad, Natasha S Crowcroft

{"title":"In Elimination Settings, Measles Antibodies Wane After Vaccination but Not After Infection: A Systematic Review and Meta-Analysis.","authors":"Shelly Bolotin, Selma Osman, Stephanie L Hughes, Archchun Ariyarajah, Andrea C Tricco, Sumaiya Khan, Lennon Li, Caitlin Johnson, Lindsay Friedman, Nazish Gul, Rachel Jardine, Maryrose Faulkner, Susan J M Hahné, Jane M Heffernan, Alya Dabbagh, Paul A Rota, Alberto Severini, Mark Jit, David N Durrheim, Walter A Orenstein, William J Moss, Sebastian Funk, Nikki Turner, William Schluter, Jaleela S Jawad, Natasha S Crowcroft","doi":"10.1093/infdis/jiac039","DOIUrl":"10.1093/infdis/jiac039","url":null,"abstract":"Background: We conducted a systematic review to assess whether measles humoral immunity wanes in previously infected or vaccinated populations in measles elimination settings.Methods: After screening 16 822 citations, we identified 9 articles from populations exposed to wild-type measles and 16 articles from vaccinated populations that met our inclusion criteria.Results: Using linear regression, we found that geometric mean titers (GMTs) decreased significantly in individuals who received 2 doses of measles-containing vaccine (MCV) by 121.8 mIU/mL (95% confidence interval [CI], -212.4 to -31.1) per year since vaccination over 1 to 5 years, 53.7 mIU/mL (95% CI, -95.3 to -12.2) 5 to 10 years, 33.2 mIU/mL (95% CI, -62.6 to -3.9), 10 to 15 years, and 24.1 mIU/mL (95% CI, -51.5 to 3.3) 15 to 20 years since vaccination. Decreases in GMT over time were not significant after 1 dose of MCV or after infection. Decreases in the proportion of seropositive individuals over time were not significant after 1 or 2 doses of MCV or after infection.Conclusions: Measles antibody waning in vaccinated populations should be considered in planning for measles elimination.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"62 1","pages":"1127-1139"},"PeriodicalIF":0.0,"publicationDate":"2022-09-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81262896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Elevated Plasma Matrix Metalloproteinase 8 Associates With Sputum Culture Positivity in Pulmonary Tuberculosis. 肺结核患者血浆基质金属蛋白酶8升高与痰培养阳性相关。

The Indonesian Journal of Infectious Diseases Pub Date : 2022-09-13 DOI: 10.1093/infdis/jiac160

N F Walker, F Karim, M Y S Moosa, S Moodley, M Mazibuko, K Khan, T R Sterling, Y F van der Heijden, A D Grant, P T Elkington, A Pym, A Leslie

引用次数: 0

Profil Tuberkulosis Paru Pada Anak di RSPI Prof. Dr. Sulianti Saroso Sulianti Saroso博士的儿童RSPI的肺结核概要

The Indonesian Journal of Infectious Diseases Pub Date : 2022-08-11 DOI: 10.32667/ijid.v8i1.134

Agatha Nagrintya Ginting, Kriston Silitonga, Suliati Suliati, Farida Murtiani

{"title":"Profil Tuberkulosis Paru Pada Anak di RSPI Prof. Dr. Sulianti Saroso","authors":"Agatha Nagrintya Ginting, Kriston Silitonga, Suliati Suliati, Farida Murtiani","doi":"10.32667/ijid.v8i1.134","DOIUrl":"https://doi.org/10.32667/ijid.v8i1.134","url":null,"abstract":"Latar belakang: Tuberkulosis (TB) adalah penyakit infeksi menular yang disebabkan oleh Mycobacterium tuberculosis (MTB) dan salah satu dari 10 penyebab kematian di dunia, 11% kasus diantaranya adalah anak-anak. Tujuan Penelitian: Penelitian ini bertujuan untuk mengetahui karakteristik, manifestasi klinis, gambaran riwayat kesehatan pasien, pengobatan, dan efek samping obat tuberculosis anak. Metode: Penelitian deskriptif. Data bersumber dari rekam medik dan form TB 01 periode Januari-Desember 2018. Hasil: Mayoritas pasien adalah anak laki-laki berusia 1-4 tahun. Manifestasi klinis batuk ditemukan sebanyak 71,8%; demam 53,8%; pembesaran KGB 43,6%; dan penurunan berat badan 33,3%. Sebagian besar (84,6%) tidak ada riwayat kontak dengan penderita TB dan 30.8% sudah mendapatkan imunisasi BCG. Sebanyak 46.2% memiliki hasil uji tuberculin positif dan hasil foto gambaran khas TB pada foto thorax. Berdasarkan riwayat kesehatan, 46.2% di antaranya bergizi baik, 89.7% merupakan pasien baru dan hanya 15 anak dengan penyakit penyerta. Pada studi ini, sebagian besar (82,1%) mendapatkan Obat Anti Tuberkulosis (OAT) anak, dengan kombinasi obat HRZ pada tahap intensif 61,5% dengan lama pengobatan 6 bulan sebanyak 48,7%. Kesimpulan: Terdapat variasi spektrum klinis yang luas pada TB anak dengan pengobatan OAT.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"43 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"81612116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Hubungan Antara Kadar Vitamin D dengan Derajat Keparahan COVID-19

The Indonesian Journal of Infectious Diseases Pub Date : 2022-08-11 DOI: 10.32667/ijid.v8i1.130

Handoko Handoko, Angki Purwanti, Dian Wahyu Tanjungsari, I. Pertiwi, Farida Murtiani

引用次数: 0

Kematian pada Pasien COVID-19 Berdasarkan Komorbid dan Tingkat Keparahan

The Indonesian Journal of Infectious Diseases Pub Date : 2022-08-11 DOI: 10.32667/ijid.v8i1.135

H. Herlina, Anita Puspitasari Dyah Nugroho, Siti Maemun, Intansari Pertiwi, Andi Dala Intan Sapta Nanda, Farida Murtiani

{"title":"Kematian pada Pasien COVID-19 Berdasarkan Komorbid dan Tingkat Keparahan","authors":"H. Herlina, Anita Puspitasari Dyah Nugroho, Siti Maemun, Intansari Pertiwi, Andi Dala Intan Sapta Nanda, Farida Murtiani","doi":"10.32667/ijid.v8i1.135","DOIUrl":"https://doi.org/10.32667/ijid.v8i1.135","url":null,"abstract":"Latar Belakang:. Penyakit Coronavirus 2019 merupakan penyakit sistem pernapasan yang baru saja muncul dan menjadi pandemi. Indonesia mengalami peningkatan jumlah kasus yang cukup drastis. Derajat keparahan yang dialami oleh pasien COVID-19 dapat dipengaruhi oleh berbagai hal seperti usia, penyakit komorbid, defisiensi vitamin D, dan obesitas. Penelitian ini bertujuan untuk mengetahui hubungan jumlah komorbid dan derajat keparahan terhadap kematian pada pasien COVID-19. Metode: Penelitian deskriptif analitik dengan rancangan cross sectional. Total sampel 1240 pasien COVID-19 RSPI Sulianti Saroso Tahun 2020 2021. Hasil: Komorbid terbanyak adalah hipertensi dan diabetes melitus, derajat keparahan kategori sedang dan outcome hidup. Hasil analisis ada hubungan antara jumlah komorbid dengan status kematian (OR=1,585). Ada hubungan diabetes melitus dengan status kematian pasien pada pasien COVID-19 (OR=1,927). Ada hubungan antara derajat keparahan dengan status kematian pada pasien COVID-19 (OR=12,699). Kesimpulan: Derajat keparahan, jumlah komorbid dan komorbid diabetes mellitus berhubungan merupakan faktor risiko kematian pada pasien COVID-19.","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"25 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"87532605","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Penerapan Posisi Pronasi Terhadap Peningkatan Oksigenasi Pada Pasien COVID-19 Dengan Pneumonia 采用新式位置，以提高19号住院病人的氧化水平和肺炎为例

The Indonesian Journal of Infectious Diseases Pub Date : 2022-08-11 DOI: 10.32667/ijid.v8i1.133

D. Kurniasih, Fitrian Rayasari, Ahmad Zubairi, S. Suryati, Kunti Wijiarti, Farida Murtiani

引用次数: 0

Hubungan Kadar Interleukin-6 (IL-6) Dengan Neutrophil Lymphocyte Ratio (NLR) Pada Pasien COVID- 19

The Indonesian Journal of Infectious Diseases Pub Date : 2022-08-11 DOI: 10.32667/ijid.v8i1.132

Sriyanto Sriyato, Lyana Setiawan, Rizana Fajrunni’mah, Farida Murtiani

{"title":"Hubungan Kadar Interleukin-6 (IL-6) Dengan Neutrophil Lymphocyte Ratio (NLR) Pada Pasien COVID- 19","authors":"Sriyanto Sriyato, Lyana Setiawan, Rizana Fajrunni’mah, Farida Murtiani","doi":"10.32667/ijid.v8i1.132","DOIUrl":"https://doi.org/10.32667/ijid.v8i1.132","url":null,"abstract":"Latar belakang: COVID-19 menjadi masalah kesehatan di dunia. Penanda inflamasi yang dapat digunakan sebagai predictor prognosis COVID-19 salah satunya Interlukin-6 (IL-6) dan Neutrofil Lymphocyte Ratio (NLR). Tujuan penelitian: mengetahui hubungan kadar IL-6 dengan NLR pada pasien COVID-19. Metode: Penelitian kuantitatif dengan desain cross sectional. Data yang dikumpulkan dari rekam medik pasien COVID-19 di RS Kanker Dharmais periode Januari-Juli 2021. Jumlah sampel sebanyak 70 pasien yang memenuhi kriteria inklusi dan eksklusi. Analisa data dilakukan secara univariat dan bivariat dengan korelasi spearman. Hasil: Dari 70 pasien COVID-19 sebagian besar berusia dalam kategori lansia akhir (56-65 Tahun) 17 (24,3%) dan jenis kelamin sebagian besar laki-laki yaitu 42 (60%). Rata-rata kadar IL-6 43,34 pg/ml dan rata-rata NLR 12,73. Ada korelasi antara kadar IL-6 dengan NLR pada pasien COVID-19 (P Value=0,000; nilai r 0.563). Kesimpulan: Adanya korelasi positif IL-6 dengan NLR. IL-6 adalah salah satu biomarker yang digunakan untuk memprediksi prognosis COVID-19 karena pemeriksaannya yg kompleks, tidak dapat memprosesnya di lab yg sederhana. Sebagai gantinya, kami menyimpulkan pemeriksaan NLR dapat menjadi biomarker alternatif. ","PeriodicalId":22572,"journal":{"name":"The Indonesian Journal of Infectious Diseases","volume":"31 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2022-08-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"75892757","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0